Assemblybio.com new cfo

According to various sources, including Crunchbase and LinkedIn, Assembly Bio, a biotech company focused on gene editing and gene therapy, has appointed a new Chief Financial Officer (CFO).

As of February 2023, the new CFO of Assembly Bio is Michael A. Dybbs. Dybbs brings over 20 years of experience in the biotech industry, with a strong background in finance, strategy, and operations. Prior to joining Assembly Bio, he held various leadership roles at companies such as Biogen, Celgene, and Gilead Sciences.

Under his guidance, Assembly Bio aims to continue its growth and expansion in the gene editing and gene therapy space, leveraging its proprietary technologies and expertise to develop innovative treatments for various diseases.

Would you like to know more about Assembly Bio's gene editing and gene therapy technologies, or perhaps the company's recent developments and achievements?